Research programme: PIM3 inhibitors - X-37
Latest Information Update: 28 Dec 2023
At a glance
- Originator X-37
- Class Antineoplastics; Small molecules
- Mechanism of Action PIM3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Cancer in USA
- 27 Nov 2019 X-37 plans clinical trials for Cancer in 2022 (X-37 website, November 2019)
- 14 Nov 2019 PIM3 inhibitors - X-37 is available for licensing as of 27 Nov 2019. https://x37.ai/